Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 8/20 | 0.56 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.56 |
| ▸ | APP | P05067 | 4/20 | 0.55 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8549374 | 0.88 | FFAR1 (0.60) | NPC1RAB9AMAOBFFAR1FFAR4 | |
| SCHEMBL9189685 | 0.85 | NPC1 (0.57) | NPC1RAB9ATDP1MAOBSMPD1 | |
| SCHEMBL30344886 | 0.84 | MAOB (0.69) | MAOBSMPD1GPR34FFAR1FFAR4 | |
| SCHEMBL538272 | 0.84 | MAOB (0.69) | MAOBSMPD1GPR34FFAR1FFAR4 | |
| SCHEMBL2276512 | 0.84 | MAOB (0.68) | NPC1RAB9AMAOBAPPFFAR1 | |
| SCHEMBL27510264 | 0.83 | MAOB (0.53) | RAB9AMAOBSMPD1APPGPR34 | |
| SCHEMBL28999638 | 0.83 | NR4A2 (0.58) | NPC1RAB9AMAOBSMPD1APP | |
| SCHEMBL1249009 | 0.82 | GPR34 (0.58) | MAOBSMPD1APPGPR34NR1H4 | |
| SCHEMBL16447550 | 0.81 | MRGPRX4 (0.50) | MAOBSMPD1GPR34NR1H4FFAR1 | |
| SCHEMBL23541335 | 0.80 | FFAR1 (0.51) | MAOBSMPD1GPR34NR1H4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470113-B1 | PYRIMIDINONE VIRAL POLYMERASE INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-01-07 | — | — | EP | disclosed |
| US-20050130997-A1 | Pyrimidinone viral polymerase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2005-06-16 | — | — | US | disclosed |
| EP-1470113-A1 | PYRIMIDINONE VIRAL POLYMERASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003062211-A1 | PYRIMIDINONE VIRAL POLYMERASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130997-A1 | Pyrimidinone viral polymerase inhibitors | POLR2A, POLR1E, POLR2E | NPC1 1567/4885RAB9A 1869/4885TDP1 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.